|  | ER |  |  | PR |  |  | HER2 |  |  | CK5 |  |  | EGFR |  |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Case | Intensity | Location | Percent | Intensity | Location | Percent | Intensity | Location | Percent | Intensity | Location | Percent | Intensity | Location | Percent |
1 | Â | Â | 0 | 1 | N* | 5 | Â | Â | 0 | 3 | M, C* | 100 | Â | Â | 0 |
2 | Â | Â | 0 | Â | Â | 0 | Â | Â | 0 | 3 | M, C | 100 | Â | Â | 0 |
3 | Â | Â | 0 | Â | Â | 0 | 2 | C, M | 20 | 3 | M | 20 | 2 | C, M | 80 |
4 | 1 | N | 40 | Â | Â | 0 | 2 | M | 20 | 3 | M | 100 | 2 | M | 15 |
5 | 1 | N | 10 | Â | Â | 0 | Â | Â | 0 | 3 | M | 30 | 2 | M | 50 |
6 | Â | Â | 0 | Â | Â | 0 | Â | Â | 0 | 3 | C, M | 40 | 1 | M | 5 |
7 | Â | Â | 0 | Â | Â | 0 | Â | Â | 0 | 3 | M, C | 80 | 1 | M | 60 |
8 | Â | Â | 0 | Â | Â | 0 | Â | Â | 0 | Â | Â | 0 | Â | Â | 0 |
9 | Â | Â | 0 | Â | Â | 0 | Â | Â | 0 | 3 | C, M | 25 | 1 | C, M | 30 |
10 | Â | Â | 0 | 1 | N | 5 | Â | Â | 0 | 3 | C, M | 5 | 1 | C | 10 |
11 | Â | Â | 0 | 3 | N | 90 | Â | Â | 0 | Â | Â | 0 | Â | Â | 0 |
12 | Â | Â | 0 | 2 | N | 80 | Â | Â | 0 | Â | Â | 0 | 1 | M | 5 |
13 | Â | Â | 0 | 1 | N | 10 | 2 | C, M | 40 | 3 | M | 80 | 1 | M, C | 15 |
14 | Â | Â | 0 | Â | Â | 0 | Â | Â | 0 | 3 | M | 100 | Â | Â | 0 |
15 | Â | Â | 0 | Â | Â | 0 | Â | Â | 0 | 3 | M, C | 70 | 1 | C, M | 30 |
16 | Â | Â | 0 | 1 | N | 30 | Â | Â | 0 | 3 | M | 50 | 2 | C, M | 50 |
17 | Â | Â | 0 | Â | Â | 0 | Â | Â | 0 | Â | Â | 0 | 2 | M, C | 30 |
18 | Â | Â | 0 | Â | Â | 0 | Â | Â | 0 | Â | Â | 0 | Â | Â | 0 |
19 | Â | Â | 0 | Â | Â | 0 | Â | Â | 0 | 3 | M, C | 90 | 2 | M | 90 |
20 | Â | Â | 0 | Â | Â | 0 | Â | Â | 0 | 3 | M | 90 | 1 | M | 80 |
21 | Â | Â | 0 | 1 | N | 5 | 2 | M | 30 | Â | Â | 0 | Â | Â | 0 |
22 | Â | Â | 0 | Â | Â | 0 | Â | Â | 0 | 3 | M | 20 | 1 | C, M | 70 |
23 | Â | Â | 0 | Â | Â | 0 | Â | Â | 0 | Â | Â | 0 | Â | Â | 0 |
24 | Â | Â | 0 | Â | Â | 0 | Â | Â | 0 | 3 | M | 70 | Â | Â | 0 |